ROR1-Targeting Antibody Specificity for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers expressing ROR1, such as chronic lymphocytic leukemia and various solid malignancies, lack effective targeted therapies, necessitating the development of ROR1-targeting antibodies for prevention, treatment, and diagnosis.
Innovation Solution
Development of ROR1-targeting antibodies with specific CDR sequences and their antigen-binding fragments, including murine, chimeric, humanized, and multispecific forms, which can be used in conjunction with chimeric antigen receptors, antibody conjugates, and engineered immune cells to target ROR1-expressing cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are used, then broad cancer coverage is achieved, but specificity and targeted killing of ROR1-expressing cells is insufficient
Solution Approach 1:
The antibody is designed with specific CDR sequences (CDR-L1: SEQ ID NO: 1, CDR-L2: SEQ ID NO: 2, CDR-L3: SEQ ID NO: 3, CDR-H1: SEQ ID NO: 4, CDR-H2: SEQ ID NO: 5, CDR-H3: SEQ ID NO: 6) that confer localized specificity to ROR1-expressing cells. This ensures the therapeutic action is concentrated precisely where ROR1 is present, minimizing effects on non-target cells while maximizing cancer cell killing efficiency
Solution Approach 2:
The patent optimizes the antibody's binding parameters including affinity and epitope recognition characteristics to achieve selective binding to ROR1. By tuning these parameters, the antibody demonstrates enhanced specificity for ROR1-positive cancer cells while maintaining minimal cross-reactivity with normal cells, thereby improving therapeutic reliability
2Reliability
If ROR1-targeting antibodies are developed, then targeted therapy effectiveness is improved, but development complexity and manufacturing difficulty increase
Solution Approach 1:
The patent provides complete amino acid sequences of the antibody variable regions and CDRs, enabling precise replication and standardization of the antibody product. This copying approach ensures consistent manufacturing quality and facilitates scalable production while maintaining the therapeutic effectiveness achieved through optimized CDR sequences
Solution Approach 2:
The antibody design incorporates universal framework regions combined with specific CDR sequences, allowing the molecule to maintain both targeted specificity and general antibody functions such as Fc-mediated effector activities. This multi-functionality simplifies manufacturing by leveraging standard antibody production platforms while achieving specialized therapeutic effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ROR1-targeting antibodies and associated immunotherapies demonstrate specific binding and killing of ROR1-expressing cancer cells, offering a potential therapeutic approach for treating cancers with minimal impact on non-target cells.
Implementation Method 1
The ROR1-targeting antibodies and associated immunotherapies demonstrate specific binding and killing of ROR1-expressing cancer cells
Data Source
AI summary
Provided are an ROR1-targeting antibody, and a multispecific antibody, a chimeric antigen receptor, an antibody conjugate, a pharmaceutical composition and a kit which comprise same, and the use thereof in the diagnosis/treatment/prevention of diseases associated with ROR1 expression.